# Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis

> **NCT07039916** · PHASE3 · RECRUITING · sponsor: **Immunovant Sciences GmbH** · enrollment: 231 (estimated)

## Conditions studied

- Generalized Myasthenia Gravis

## Interventions

- **DRUG:** IMVT-1402
- **DRUG:** IMVT-1402
- **DRUG:** Placebo
- **DRUG:** IMVT-1402

## Key facts

- **NCT ID:** NCT07039916
- **Lead sponsor:** Immunovant Sciences GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-27
- **Primary completion:** 2027-12
- **Final completion:** 2028-12
- **Target enrollment:** 231 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07039916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07039916, "Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07039916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*